187 related articles for article (PubMed ID: 38848534)
1. Adverse Cardiovascular Effects of COVID-19 Vaccination: A Systematic Review.
Huang JH; Ju KS; Liao TW; Lin YK; Yeh JS; Chen YJ
Cardiol Rev; 2024 Jul-Aug 01; 32(4):314-319. PubMed ID: 38848534
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis.
Velikova T; Georgiev T
Rheumatol Int; 2021 Mar; 41(3):509-518. PubMed ID: 33515320
[TBL] [Abstract][Full Text] [Related]
3. COVID-19: Coronavirus Vaccine Development Updates.
Zhao J; Zhao S; Ou J; Zhang J; Lan W; Guan W; Wu X; Yan Y; Zhao W; Wu J; Chodosh J; Zhang Q
Front Immunol; 2020; 11():602256. PubMed ID: 33424848
[TBL] [Abstract][Full Text] [Related]
4. [SARS-CoV-2 vaccines].
Benfield TL; Helweg-Larsen J
Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
[TBL] [Abstract][Full Text] [Related]
5. Transverse Myelitis Following SARS-CoV-2 Vaccination: A Pharmacoepidemiological Study in the World Health Organization's Database.
Nguyen S; Bastien E; Chretien B; Sassier M; Defer G; Nehme A; Lelong-Boulouard V; Alexandre J; Fedrizzi S; Morice PM
Ann Neurol; 2022 Dec; 92(6):1080-1089. PubMed ID: 36054163
[TBL] [Abstract][Full Text] [Related]
6. An Insight Into Pathophysiology, Epidemiology, and Management of Cardiovascular Complications of SARS-CoV-2 Infection, Post-acute COVID Syndrome, and COVID Vaccine.
Davoudi F; Miyashita S; Yoo TK; Lee PT; Foster GP
Crit Pathw Cardiol; 2022 Sep; 21(3):123-129. PubMed ID: 35994720
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 vaccines: concerns beyond protective efficacy and safety.
Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
[TBL] [Abstract][Full Text] [Related]
8. A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines.
Ghasemiyeh P; Mohammadi-Samani S; Firouzabadi N; Dehshahri A; Vazin A
Int Immunopharmacol; 2021 Nov; 100():108162. PubMed ID: 34562844
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
10. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
Front Immunol; 2021; 12():658519. PubMed ID: 34276652
[TBL] [Abstract][Full Text] [Related]
11. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
Gong W; Parkkila S; Wu X; Aspatwar A
Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
[TBL] [Abstract][Full Text] [Related]
13. Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis.
Stefanou MI; Palaiodimou L; Theodorou A; Christodoulou MV; Tzartos JS; Tzanetakos D; Kitsos D; Chondrogianni M; Zouvelou V; Dardiotis E; Tzavellas E; Syrigou E; Benetou V; Paraskevas GP; Tsiodras S; Tsivgoulis G; Giannopoulos S
Mult Scler; 2023 Apr; 29(4-5):585-594. PubMed ID: 36722184
[TBL] [Abstract][Full Text] [Related]
14. An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.
Motamedi H; Ari MM; Dashtbin S; Fathollahi M; Hossainpour H; Alvandi A; Moradi J; Abiri R
Int Immunopharmacol; 2021 Jul; 96():107763. PubMed ID: 34162141
[TBL] [Abstract][Full Text] [Related]
15. [Vaccination contre le SARS-CoV-2, le Graal ?].
Binh Luong Nguyen L; Lachâtre M; Launay O
Rev Prat; 2022 May; 72(5):517-522. PubMed ID: 35899638
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 and cardiovascular disease: manifestations, pathophysiology, vaccination, and long-term implication.
Abdel Moneim A; Radwan MA; Yousef AI
Curr Med Res Opin; 2022 Jul; 38(7):1071-1079. PubMed ID: 35575011
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
18. Advances in the design and development of SARS-CoV-2 vaccines.
Peng XL; Cheng JS; Gong HL; Yuan MD; Zhao XH; Li Z; Wei DX
Mil Med Res; 2021 Dec; 8(1):67. PubMed ID: 34911569
[TBL] [Abstract][Full Text] [Related]
19. A perspective on SARS-CoV-2 virus-like particles vaccines.
Gao X; Xia Y; Liu X; Xu Y; Lu P; Dong Z; Liu J; Liang G
Int Immunopharmacol; 2023 Feb; 115():109650. PubMed ID: 36649673
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 Vaccination in Korea: Past, Present, and the Way Forward.
Nham E; Song JY; Noh JY; Cheong HJ; Kim WJ
J Korean Med Sci; 2022 Dec; 37(47):e351. PubMed ID: 36472087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
